# Investigating the Impact of ABCB1 3435C>T (rs1045642) Variant on Severity and Cognitive Decline in Egyptian Alzheimer’s Disease Patients

**Authors:** Yasmeen K. Farouk, Nahla Elsayed Nagy, Azza M. El Amir, Neveen Adel Madbouly, Nashwa El-Khazragy

PMC · DOI: 10.1007/s12035-026-05789-w · Molecular Neurobiology · 2026-03-26

## TL;DR

This study explores how a specific genetic variant affects Alzheimer's disease severity and cognitive decline in Egyptian patients.

## Contribution

The study identifies the ABCB1 3435C>T (rs1045642) variant as a risk factor for Alzheimer's severity and cognitive decline in an Egyptian cohort.

## Key findings

- The TT genotype is associated with increased Alzheimer's disease risk and severe cognitive decline.
- CC genotype carriers show milder dementia and better cognitive scores.
- Genotyping ABCB1 3435C>T could help in risk stratification and monitoring disease progression.

## Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with a complex genetic risk. The ABCB1 gene encodes P-glycoprotein, a blood-brain barrier efflux transporter involved in amyloid-β (Aβ) clearance. Variants in ABCB1 3435C>T (rs1045642) may influence AD susceptibility and severity, but data from Middle Eastern populations remain limited. The objective of the study is to investigate the ABCB1 3435C>T (rs1045642) polymorphism with AD susceptibility, dementia severity, and cognitive impairment in an Egyptian cohort. A case–control study was conducted on 300 subjects, including 150 cognitively healthy controls and 150 clinically diagnosed AD patients. Genotyping for ABCB1 3435C>T (rs1045642) was performed by polymerase chain reaction (PCR). Associations between genotype distribution and AD risk, Clinical Dementia Rating (CDR) scores, and Mini-Mental State Examination (MMSE) categories were analyzed. Logistic regression and Fisher’s exact tests were applied to calculate odds ratios (OR) and 95% confidence intervals (CI). The CC genotype was significantly more frequent among controls (64.8%) compared with AD patients (35.2%), whereas the TT genotype predominated in AD (70.5% vs 29.5%). CC carriers were enriched in mild dementia and higher MMSE categories, while TT carriers dominated in severe dementia and lower MMSE groups. Logistic regression confirmed that TT carriers had a 4.4-fold increased risk of AD compared with CC (p < 0.001) and a 13.3-fold higher likelihood of scoring < 20 on MMSE (p < 0.001). The ABCB1 3435C>T (rs1045642) variant significantly influences AD susceptibility and cognitive decline in Egyptians, with TT conferring risk and CC exerting a protective effect. Genotyping may aid risk stratification and monitoring of disease progression.

Association of ABCB1 3435C>T (rs1045642) variant with AD severity and neuropsychological symptoms. The ABCB1 3435C>T (rs1045642) variant was associated with increased AD severity and more pronounced neuropsychological symptoms among Egyptian patients, suggesting a potential genetic influence on disease progression and symptom manifestation

## Linked entities

- **Genes:** ABCB1 (ATP binding cassette subfamily B member 1) [NCBI Gene 5243]
- **Proteins:** Mdr65 (Multi drug resistance 65)
- **Diseases:** Alzheimer’s disease (MONDO:0004975)

## Full-text entities

- **Genes:** AGER (advanced glycosylation end-product specific receptor) [NCBI Gene 177] {aka RAGE, SCARJ1, sRAGE}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, NR1I2 (nuclear receptor subfamily 1 group I member 2) [NCBI Gene 8856] {aka BXR, ONR1, PAR, PAR1, PAR2, PARq}, PGP (phosphoglycolate phosphatase) [NCBI Gene 283871] {aka AUM, G3PP, PGPase}, PSEN1 (presenilin 1) [NCBI Gene 5663] {aka ACNINV3, AD3, CMD1U, FAD, PS-1, PS1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, ABCB1 (ATP binding cassette subfamily B member 1) [NCBI Gene 5243] {aka ABC20, CD243, CLCS, ENPAT, GP170, MDR1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, PSEN2 (presenilin 2) [NCBI Gene 5664] {aka AD3L, AD4, CMD1V, PS2, STM2}
- **Diseases:** stroke (MESH:D020521), schizophrenia (MESH:D012559), epilepsy (MESH:D004827), Clinical (MESH:D000075902), depression (MESH:D003866), psychosis (MESH:D011618), Cognitive Decline (MESH:D003072), Parkinson's disease (MESH:D010300), sleep disturbances (MESH:D012893), neurotoxic (MESH:D020258), alcohol or substance abuse (MESH:D019966), neuroinflammation (MESH:D000090862), mitochondrial dysfunction (MESH:D028361), neurological diseases (MESH:D020271), neurodegeneration (MESH:D019636), Dementia (MESH:D003704), agitation (MESH:D011595), neuropsychological illness (MESH:D002908), bipolar disorder (MESH:D001714), neuropsychiatric (MESH:C000631768), amyloid (MESH:C000718787), hepatic, renal, or cardiac failure (MESH:D006333), AD (MESH:D000544), memory loss (MESH:D008569), anxiety (MESH:D001007), neurological or psychological disorders (MESH:D020018), inflammatory (MESH:D007249)
- **Chemicals:** ADP adenosine-3-phosphate (-), malondialdehyde (MESH:D008315), MDA (MESH:D015104), EDTA (MESH:D004492), lipid (MESH:D008055), N-Methyl-D-aspartate (MESH:D016202), ROS (MESH:D017382), phosphatidylinositol-3-phosphate (MESH:C055525)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** 3435C>T

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13018025/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13018025/full.md

---
Source: https://tomesphere.com/paper/PMC13018025